|Awarded On||August 19, 2020|
|Title||SERBP1, Epigenetic Regulation and Glioblastoma Targeting|
|Award Mechanism||High Impact/High Risk|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Luiz Penalva|
|Cancer Sites||Brain and Other Nervous System|
*Pending contract negotiation
To expand on pathways driving glioblastoma (GBM) and create new routes for therapy, my lab has been focusing on oncogenic RNA binding proteins (RBPs). RBPs are critical regulators of gene expression and are often altered in cancer. We have identified SERBP1 (Serpine RNA binding protein 1) as a novel oncogenic RBP in GBM. SERBP1 high expression correlates with poor patient prognosis and influences treatment response. We established that SERBP1 regulates critical metabolic routes (One Carbon, Methyl and MTA cycles) and this regulation leads to activation of cell cycle, tumor growth, proliferation of glioma stem cells and silencing of genes implicated in neuronal differentiation. Our study has ...